Lysosomal-associated protein transmembrane 5 ameliorates non-alcoholic steatohepatitis by promoting the degradation of CDC42 in mice
暂无分享,去创建一个
Jing Zhao | Lang Jiang | Hao Liu | Peiwen Yang | Xiaoyue Xiao | P. Ye | J. Xia | Manhua Chen | Shan Hu | S. Tian | Qin Yang | Zhen Liu | Mei Li | Peiwen Yang | Qin Yang | Mei Li | Hao Liu | Xiaoyue Xiao | Song Tian | Sha Hu
[1] W. Diao,et al. Lysosomal protein transmembrane 5 promotes lung-specific metastasis by regulating BMPR1A lysosomal degradation , 2022, Nature Communications.
[2] R. Malekzadeh,et al. The global NAFLD policy review and preparedness index: Are countries ready to address this silent public health challenge? , 2021, Journal of hepatology.
[3] Lu Gao,et al. Lysosomal-Associated Protein Transmembrane 5 Functions as a Novel Negative Regulator of Pathological Cardiac Hypertrophy , 2021, Frontiers in Cardiovascular Medicine.
[4] A. Suzuki,et al. Hepatic Mitochondrial SAB Deletion or Knockdown Alleviates Diet‐Induced Metabolic Syndrome, Steatohepatitis, and Hepatic Fibrosis , 2021, Hepatology.
[5] Haibo Ding,et al. Vpr counteracts the restriction of LAPTM5 to promote HIV-1 infection in macrophages , 2021, Nature Communications.
[6] K. Dou,et al. Tripartite motif 16 ameliorates nonalcoholic steatohepatitis by promoting the degradation of phospho-TAK1. , 2021, Cell metabolism.
[7] Yuquan Wei,et al. Role of lysosomes in physiological activities, diseases, and therapy , 2021, Journal of Hematology & Oncology.
[8] C. Eapen,et al. What Are the Current Pharmacological Therapies for Nonalcoholic Fatty Liver Disease? , 2020, Journal of clinical and experimental hepatology.
[9] Feng-Sheng Wang,et al. miR-29a Modulates GSK3β/SIRT1-Linked Mitochondrial Proteostatic Stress to Ameliorate Mouse Non-Alcoholic Steatohepatitis , 2020, International journal of molecular sciences.
[10] M. Hwang,et al. Lumenal Galectin-9-Lamp2 interaction regulates lysosome and autophagy to prevent pathogenesis in the intestine and pancreas , 2020, Nature Communications.
[11] P. Trivedi,et al. Lysosomal Biology and Function: Modern View of Cellular Debris Bin , 2020, Cells.
[12] Yusu Gu,et al. Systemic AAV9.LAMP2B injection reverses metabolic and physiologic multiorgan dysfunction in a murine model of Danon disease , 2020, Science Translational Medicine.
[13] Hongliang Li,et al. Emerging Molecular Targets for Treatment of Nonalcoholic Fatty Liver Disease , 2019, Trends in Endocrinology & Metabolism.
[14] S. Muller,et al. Lysosomes as a therapeutic target , 2019, Nature Reviews Drug Discovery.
[15] H. Zhang,et al. Dual‐Specificity Phosphatase 26 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through Transforming Growth Factor Beta–Activated Kinase 1 Suppression , 2019, Hepatology.
[16] M. Febbraio,et al. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They? , 2019, Cell metabolism.
[17] P. Ye,et al. Dual‐Specificity Phosphatase 9 Protects Against Nonalcoholic Fatty Liver Disease in Mice Through ASK1 Suppression , 2018, Hepatology.
[18] Hongliang Li,et al. Insights into the Epidemiology, Pathogenesis, and Therapeutics of Nonalcoholic Fatty Liver Diseases , 2018, Advanced science.
[19] Hongliang Li,et al. Tmbim1 is a multivesicular body regulator that protects against non-alcoholic fatty liver disease in mice and monkeys by targeting the lysosomal degradation of Tlr4 , 2017, Nature Medicine.
[20] Roberto Zoncu,et al. The Lysosome as a Regulatory Hub. , 2016, Annual review of cell and developmental biology.
[21] A. Gentilini,et al. Molecular Pathogenesis of NASH , 2016, International journal of molecular sciences.
[22] T. Tsubata,et al. LAPTM5 promotes lysosomal degradation of intracellular CD3ζ but not of cell surface CD3ζ , 2014, Immunology and cell biology.
[23] T. Kurosaki,et al. A Role for Lysosomal-Associated Protein Transmembrane 5 in the Negative Regulation of Surface B Cell Receptor Levels and B Cell Activation , 2010, The Journal of Immunology.
[24] K. Das,et al. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease , 2010, Hepatology.
[25] J. Taylor,et al. Autophagy and the ubiquitin-proteasome system: collaborators in neuroprotection. , 2008, Biochimica et biophysica acta.
[26] M. Hatano,et al. A lysosomal protein negatively regulates surface T cell antigen receptor expression by promoting CD3zeta-chain degradation. , 2008, Immunity.
[27] D. Rotin,et al. Transport of LAPTM5 to lysosomes requires association with the ubiquitin ligase Nedd4, but not LAPTM5 ubiquitination , 2006, The Journal of cell biology.
[28] M. Pagliassotti,et al. Hepatospecific effects of fructose on c-jun NH2-terminal kinase: implications for hepatic insulin resistance. , 2004, American journal of physiology. Endocrinology and metabolism.
[29] Tzu-Ling Cheng,et al. Regulation of anoikis by Cdc42 and Rac1. , 2004, Experimental cell research.
[30] J. Rowley,et al. LAPTM5: a novel lysosomal-associated multispanning membrane protein preferentially expressed in hematopoietic cells. , 1996, Genomics.
[31] Yi Luo,et al. Downregulation of LAPTM5 suppresses cell proliferation and viability inducing cell cycle arrest at G0/G1 phase of bladder cancer cells. , 2017, International journal of oncology.
[32] F. Urano,et al. Cdc42 and Rac1 are major contributors to the saturated fatty acid-stimulated JNK pathway in hepatocytes. , 2012, Journal of hepatology.